Vivacta Biotechnology is a biopharmaceutical company headquartered in Shanghai, China, specializing in innovative biotechnology research. The company is focused on developing in vivo CAR-T therapies utilizing a targeted delivery system.
Subscribe to see VIVACTA Biotechnology’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
VIVACTA Biotechnology is a drug discovery company headquartered in Shanghai, China. Its most recent funding round, Series A, raised $50M in April 2026. Xcout tracks 1 named person at VIVACTA Biotechnology, including Liu Yarong (Founder and CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $50M | 11 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of VIVACTA Biotechnology's closest competitors — see the full list of competitors and alternatives →
LyncBio Therapeutics is an innovative drug discovery and development company headquartered in Shanghai, China, with research facilities in Suzhou. The firm specializes in the advancement of antibody-drug conjugate (ADC) therapeutics.
Vivacelle Bio, Inc. is a Chicago-based developmental-stage biotechnology company pioneering innovative intravenous fluid therapies for treating conditions like sepsis and organ failure.
iRegene Therapeutics is a biotechnology company headquartered in Wuhan, China, with additional facilities in Suzhou. The firm specializes in regenerative medicine and advanced cell therapies designed to redefine modern medicine.
BobcatBio, Inc. is a clinical-stage biotechnology company founded in 2020 and headquartered in Hummelstown, Pennsylvania. The company focuses on developing macrophage-based cell therapies and cancer-specific immunotherapies, including its lead cellular therapy candidate RB-1355, for the treatment of solid tumors.
META Pharmaceuticals Inc. is a pioneering biotechnology company focusing on immuno-metabolism and gastrointestinal therapeutics within immunology, operating research efforts connected to JLABS in Shanghai.
Immitra Bio GmbH is a biotechnology startup and ETH Zürich spin-off developing a scalable in-vivo genetic medicine platform to treat rare genetic diseases. Headquartered in Schlieren, Switzerland, the company secured early-stage venture funding to advance its gene-editing therapies.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about VIVACTA Biotechnology? Suggest a correction · Work at VIVACTA Biotechnology? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.